207 related articles for article (PubMed ID: 18828153)
1. Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel.
Griffin S; Stgelais C; Owsianka AM; Patel AH; Rowlands D; Harris M
Hepatology; 2008 Dec; 48(6):1779-90. PubMed ID: 18828153
[TBL] [Abstract][Full Text] [Related]
2. Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel.
Foster TL; Verow M; Wozniak AL; Bentham MJ; Thompson J; Atkins E; Weinman SA; Fishwick C; Foster R; Harris M; Griffin S
Hepatology; 2011 Jul; 54(1):79-90. PubMed ID: 21520195
[TBL] [Abstract][Full Text] [Related]
3. Inhibitor Development against p7 Channel in Hepatitis C Virus.
Wei S; Hu X; Du L; Zhao L; Xue H; Liu C; Chou JJ; Zhong J; Tong Y; Wang S; OuYang B
Molecules; 2021 Mar; 26(5):. PubMed ID: 33802584
[TBL] [Abstract][Full Text] [Related]
4. Cell viability assay as a tool to study activity and inhibition of hepatitis C p7 channels.
Breitinger U; Farag NS; Ali NKM; Ahmed M; El-Azizi MA; Breitinger HG
J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33709903
[TBL] [Abstract][Full Text] [Related]
5. Intracellular proton conductance of the hepatitis C virus p7 protein and its contribution to infectious virus production.
Wozniak AL; Griffin S; Rowlands D; Harris M; Yi M; Lemon SM; Weinman SA
PLoS Pathog; 2010 Sep; 6(9):e1001087. PubMed ID: 20824094
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission.
Meredith LW; Zitzmann N; McKeating JA
Antiviral Res; 2013 Dec; 100(3):636-9. PubMed ID: 24157306
[TBL] [Abstract][Full Text] [Related]
7. Patch-Clamp Study of Hepatitis C p7 Channels Reveals Genotype-Specific Sensitivity to Inhibitors.
Breitinger U; Farag NS; Ali NKM; Breitinger HA
Biophys J; 2016 Jun; 110(11):2419-2429. PubMed ID: 27276260
[TBL] [Abstract][Full Text] [Related]
8. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus.
Steinmann E; Whitfield T; Kallis S; Dwek RA; Zitzmann N; Pietschmann T; Bartenschlager R
Hepatology; 2007 Aug; 46(2):330-8. PubMed ID: 17599777
[TBL] [Abstract][Full Text] [Related]
9. "Too little, too late?" Will inhibitors of the hepatitis C virus p7 ion channel ever be used in the clinic?
Griffin S
Future Med Chem; 2014; 6(17):1893-907. PubMed ID: 25495983
[TBL] [Abstract][Full Text] [Related]
10. Symmetric dimeric adamantanes for exploring the structure of two viroporins: influenza virus M2 and hepatitis C virus p7.
Mandour YM; Breitinger U; Ma C; Wang J; Boeckler FM; Breitinger HG; Zlotos DP
Drug Des Devel Ther; 2018; 12():1019-1031. PubMed ID: 29750015
[TBL] [Abstract][Full Text] [Related]
11. A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria.
Griffin SDC; Harvey R; Clarke DS; Barclay WS; Harris M; Rowlands DJ
J Gen Virol; 2004 Feb; 85(Pt 2):451-461. PubMed ID: 14769903
[TBL] [Abstract][Full Text] [Related]
12. Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release.
Foster TL; Thompson GS; Kalverda AP; Kankanala J; Bentham M; Wetherill LF; Thompson J; Barker AM; Clarke D; Noerenberg M; Pearson AR; Rowlands DJ; Homans SW; Harris M; Foster R; Griffin S
Hepatology; 2014 Feb; 59(2):408-22. PubMed ID: 24022996
[TBL] [Abstract][Full Text] [Related]
13. Determinants of hepatitis C virus p7 ion channel function and drug sensitivity identified in vitro.
StGelais C; Foster TL; Verow M; Atkins E; Fishwick CW; Rowlands D; Harris M; Griffin S
J Virol; 2009 Aug; 83(16):7970-81. PubMed ID: 19493992
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine.
Castelain S; Bonte D; Penin F; François C; Capron D; Dedeurwaerder S; Zawadzki P; Morel V; Wychowski C; Duverlie G
J Med Virol; 2007 Feb; 79(2):144-54. PubMed ID: 17177298
[TBL] [Abstract][Full Text] [Related]
15. Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C.
Vermehren A; Welsch C; Elsler U; Vermehren J; Herrmann E; Sarrazin C; von Wagner M; Susser S; Hofmann WP; Kronenberger B; Zeuzem S; Mihm U
Antivir Ther; 2013; 18(6):803-11. PubMed ID: 23824381
[TBL] [Abstract][Full Text] [Related]
16. Computational Docking Study of p7 Ion Channel from HCV Genotype 3 and Genotype 4 and Its Interaction with Natural Compounds.
Mathew S; Fatima K; Fatmi MQ; Archunan G; Ilyas M; Begum N; Azhar E; Damanhouri G; Qadri I
PLoS One; 2015; 10(6):e0126510. PubMed ID: 26030803
[TBL] [Abstract][Full Text] [Related]
17. The stability of secreted, acid-labile H77/JFH-1 hepatitis C virus (HCV) particles is altered by patient isolate genotype 1a p7 sequences.
Atkins E; Tatineni R; Li H; Gretch D; Harris M; Griffin S
Virology; 2014 Jan; 448():117-24. PubMed ID: 24314642
[TBL] [Abstract][Full Text] [Related]
18. Amino acid variations in hepatitis C virus p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C.
Mihm U; Grigorian N; Welsch C; Herrmann E; Kronenberger B; Teuber G; von Wagner M; Hofmann WP; Albrecht M; Lengauer T; Zeuzem S; Sarrazin C
Antivir Ther; 2006; 11(4):507-19. PubMed ID: 16856625
[TBL] [Abstract][Full Text] [Related]
19. Rationally derived inhibitors of hepatitis C virus (HCV) p7 channel activity reveal prospect for bimodal antiviral therapy.
Shaw J; Gosain R; Kalita MM; Foster TL; Kankanala J; Mahato DR; Abas S; King BJ; Scott C; Brown E; Bentham MJ; Wetherill L; Bloy A; Samson A; Harris M; Mankouri J; Rowlands DJ; Macdonald A; Tarr AW; Fischer WB; Foster R; Griffin S
Elife; 2020 Nov; 9():. PubMed ID: 33169665
[TBL] [Abstract][Full Text] [Related]
20. Computational Study of HCV p7 Channel: Insight into a New Strategy for HCV Inhibitor Design.
Ying B; Pang S; Yang J; Zhong Y; Wang J
Interdiscip Sci; 2019 Jun; 11(2):292-299. PubMed ID: 30194627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
